Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SOX regimen in advanced biliary tract or ampullary adenocarcinoma
NCT01180153Phase 2Unknown
- Sponsor
- Peking University Cancer Hospital & Institute
- Start
- Aug 2010
- Primary completion
- Aug 2012
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
A Phase 2 trial of tegafur, oxaliplatin in biliary tract cancer (BTC), ampullary adenocarcinoma, sponsored by Peking University Cancer Hospital & Institute. Status: unknown.
02
Drugs
tegafuroxaliplatin
03
Conditions
biliary tract cancer (BTC)ampullary adenocarcinoma
Beyond the preview
Go deeper on NCT01180153.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01180153.